Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 88, Issue -, Pages 134-137Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2017.01.051
Keywords
Anti-angiogenics; Tumor microenvironment; Regulatory T cells
Funding
- National Natural Science Foundation of China [81472792]
- National Natural Science Foundation of Jiangsu Province [BK20151279]
- Youth Talents Found of Lianyungang First People's Hospital [QN150101]
Ask authors/readers for more resources
A benefit of anti-angiogenic drugs is improved tumor immune tolerance. Regulatory T cells (Tregs) in the tumor microenvironment mediate tumor immune tolerance and anti-angiogenic drugs not only indirectly affect Tregs via dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) but they can also act directly on Tregs causing immunosuppression. Specifically, these drugs may induce differentiation and chemotaxis and reduce the number and function of Tregs by targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and neuropilin-1 (NRP-1) on the cell surface. Recently, anti-angiogenic drugs have been documented to promote a new way of thinking about tumor immunotherapy: clinical application of Tregs and related immunosuppressive molecules may be promising targets for synergistic tumor immunotherapy. (C) 2017 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available